Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24819196 | 0.78 | NPSR1 (0.42) | LCKNPSR1MEN1HPGDKMT2A | |
| SCHEMBL30050421 | 0.78 | NPSR1 (0.42) | LCKNPSR1MEN1HPGDKMT2A | |
| SCHEMBL29284926 | 0.74 | CYP3A4 (0.36) | NPSR1MEN1HPGDKMT2AMAPT | |
| SCHEMBL18181782 | 0.72 | HTR3A (0.38) | ATRPARP1PTGS1PTGS2 | |
| SCHEMBL29284905 | 0.72 | PARP1 (0.39) | NPSR1HPGDMAPTRXFP1PARP1 | |
| SCHEMBL25166466 | 0.71 | MEN1 (0.46) | CA12CA1CA9NPSR1MEN1 | |
| SCHEMBL30148354 | 0.70 | SMN1; SMN2 (0.39) | CA12CA1CA9NPSR1MEN1 | |
| SCHEMBL16716145 | 0.70 | SMN1; SMN2 (0.39) | CA12CA1CA9NPSR1MEN1 | |
| SCHEMBL18181784 | 0.70 | AAK1 (0.33) | CA12CA1CA9NPSR1MEN1 | |
| SCHEMBL3416923 | 0.70 | NPSR1 (0.38) | CA1CA9NPSR1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4408843-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023056264-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | LCK 4535/4885CA12 4645/4885CA1 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.